Scientists Identify a Key Morphine Regulator that May Reduce Risk of Pain-Killer Abuse and Addiction

By Eric Sauter

Once used in the 18^th century as currency to reverse the trade imbalance between China and Britain, opiates that contain morphine have been misunderstood (and misused) almost continually ever since.

Morphine works its euphoric effect by acting on a specific protein that has been part of vertebrate anatomy for nearly a half-billion years. Despite that lengthy pedigree, regulation of these receptor proteins has never been well understood.

A new study led by Kirill Martemyanov, an associate professor on the Florida campus of The Scripps Research Institute (TSRI), has shown that a specific molecule controls morphine receptor signaling in a small group of brain cells. The findings could lead to a new drug target for developing less-addictive pain medications and even offer a clue to the genetic predisposition of patients to addiction before treatment.

The study was published recently online ahead of print by the journal Biological Psychiatry.

The molecule in question is known as a regulator of G protein signaling (RGS) protein, which controls the morphine receptor (mu opioid receptor). Using genetically modified animal models lacking a particular RGS protein called RGS7, a protein abundant in the brain, the study showed that eliminating the protein enhanced reward, increased pain relief, delayed tolerance and heightened withdrawal in response to self-administered morphine doses. In other words, without the protein, the animals were predisposed to morphine addiction.

“The mu opioid receptor acts as a conductor of the drug’s effects, while RGS7 acts as a brake on the signal,” Martemyanov said. “The animals could press a lever to receive an infusion of morphine. We looked at the number of lever presses to determine how much they liked it and, judging from this test, mice lacking RGS7 craved the drug much more than their normal siblings.”

RGS7 appears to exert its effects by regulating morphine-induced changes in excitability of neurons and plasticity of synapses—the ability of the synapse, the junction between two nerve cells, to change its function.

“This study reveals a unique modulatory role of RGS7 in a brain-region-specific action to morphine use and indicates RGS7 as a potential drug target,” said Research Associate Laurie P. Sutton, the first author of the study. “Pharmacological intervention at the level of RGS7 may reduce some of the detrimental side-effects associated with opiates.”

Martemyanov believes there is a strong diagnostic future for their discovery.

“If our findings hold true for human patients, you could look specifically for RGS7 levels for any disabling mutation with a simple blood test,” he said. “Mutations could indicate a strong reaction to a drug such as morphine—people carrying a deficient copy of the RGS7 gene might need much lower doses of opioids and could be cautioned to be extra careful with these substances.”

This might also shed light on why some people have such a difficult time with addiction to drugs such as morphine, while others are not so susceptible, Martemyanov noted.

Surprisingly, in addition to drug craving, the animals lacking RGS7 also worked harder to obtain a food reward, further suggesting that RGS7 may be a more general regulator of reward behavior extending beyond drug-induced euphoria.

In addition to Sutton and Martemyanov, other authors of the study, “RGS7 Regulates Reward Behavior by Controlling Opioid Signaling in the Striatum,” were Olga Ostrovskaya, Maria Dao, Keqiang Xie, Cesare Orlandi, Roy Smith and Sunmee Wee, all of TSRI at the time of the study. For more information, see http://www.biologicalpsychiatryjournal.com/article/S0006-3223(15)00653-8/abstract

This work was supported by the National Institutes of Health (grants DA026405, DA036082 and DA036596) and the Canadian Institutes of Health.

Send comments to: press[at]scripps.edu